Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Adult Acute Myeloid Leukemia in Remission: early-phase trial registry

A small indexed set (15 trials) with no open enrollment listed right now.

Corpus placement: #1,140 of 28,707 conditions by registered trial count.

15 US clinical trials · none currently recruiting · #1,140 of 28,707 conditions by registered trial count

Adult Acute Myeloid Leukemia in Remission: 15 US clinical trials tracked, none currently recruiting.

Adult Acute Myeloid Leukemia in Remission is the subject of 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 8 of these trials.

Enrollment posture brief

Registry condition adult-acute-myeloid-leukemia-in-remission

OPEN 0 | RECR 0% | LATE 2 | EARLY 9 | RANK #1140 | SPON 8

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Advanced Lung Non-Small Cell53.3%Anatomic Stage 0 Breast Canc40%AIDS26.7%Adult Glioblastoma0%Adult Acute Myeloid Leuk (th…0%
Open-enrollment share among volume-matched conditions near Adult Acute Myeloid Leukemia in Remission

Adult Acute Myeloid Leukemia in Remission has no open enrollment in this registry pull (15 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adult Acute Myeloid Leukemia in Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adult Acute Myeloid Leukemia in Remission is recruiting below its size-band peers.

    0 of 15 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Adult Acute Myeloid Leukemia in Remission research.

    Fred Hutchinson Cancer Center accounts for 8 of 15 trials (53.3%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Adult Acute Myeloid Leukemia in Remission trials plan to enrol fewer than 100 people.

    Median target enrolment is 33 among the 15 trials that report a genuine target (sentinel values excluded). 10 of those (66.7%) plan for fewer than 100 participants.

  4. Adult Acute Myeloid Leukemia in Remission research is mostly interventional.

    14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 25Phase 32

Indexed trials (enrollment closed)

15 total, page 1 of 1

ACTIVE NOT RECRUITING 153 participants

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

City of Hope Medical Center

NCT01199562

ACTIVE NOT RECRUITING Phase 2 72 participants

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

City of Hope Medical Center

NCT01885689

ACTIVE NOT RECRUITING Phase 1 31 participants

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

City of Hope Medical Center

NCT02159495

COMPLETED Phase 3 1,337 participants

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

NCT00799461

COMPLETED Phase 2 210 participants

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

NCT00105001

COMPLETED Phase 2 140 participants

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

NCT00489203

COMPLETED Phase 1 106 participants

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Fred Hutchinson Cancer Center

NCT00027820

COMPLETED NA 52 participants

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

NCT00445744

COMPLETED Phase 1 33 participants

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Sumithira Vasu

NCT02122081

COMPLETED Phase 3 25 participants

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

NCT00322101

COMPLETED Phase 1 23 participants

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Fred Hutchinson Cancer Center

NCT00343798

COMPLETED NA 20 participants

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT00408681

COMPLETED Phase 2 20 participants

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

University of Wisconsin, Madison

NCT01707004

COMPLETED Phase 2 15 participants

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Nohla Therapeutics

NCT01175785

COMPLETED NA 5 participants

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Fred Hutchinson Cancer Center

NCT00112593

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 2

Named interventions

Most-linked intervention names on Adult Acute Myeloid Leukemia in Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

cyclophosphamide Drug
7 trials
tacrolimus Drug
5 trials
fludarabine phosphate Drug
4 trials
mycophenolate mofetil Drug
3 trials
total-body irradiation Radiation
3 trials
busulfan Drug
3 trials
methotrexate Drug
3 trials
allogeneic hematopoietic stem cell transplantation Procedure
3 trials

US sites by state

Facility locations filed on Adult Acute Myeloid Leukemia in Remission trials. A trial with sites in several states counts in each.

Washington 10 trials
California 5 trials
Wisconsin 4 trials
Utah 3 trials
Georgia 3 trials
Colorado 3 trials
Texas 1 trials
Oregon 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adult Acute Myeloid Leukemia in Remission page

15 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Adult Acute Myeloid Leukemia in Remission trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Fred Hutchinson Cancer Center sponsors the most Adult Acute Myeloid Leukemia in Remission trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Acute Myeloid Leukemia in Remission condition card totals 15 registered trials; most-linked intervention cyclophosphamide; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.